All In Biotech

Drug Trial Radar · NCT06565611

A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Clinical Study Investigating the Safety, Tolerability, and Effectiveness of the Co-Administration of Bremelanotide With Tirzepatide (GLP-1/GIP) for the Treatment of Obesity

Last checked: Nov 19, 2026Latest source record: Mar 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

108

Planned (sponsor's estimate)

Start

Aug 5, 2024

Primary completion

Feb 5, 2025

Study completion Mar 31, 2025

Sponsor

Lead sponsor
Palatin Technologies, IncIndustry
Sponsor type
Industry
First posted
Aug 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective, randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of bremelanotide (BMT) used in combination with tirzepatide therapy in the treatment of obesity in subjects with a BMI ranging from 30.0 to 45.0 kg/m2 (inclusive).

Conditions

  • Obesity

Interventions

  • bremelanotideDrug

    bremelanotide (BMT) sterile aqueous solution for subcutaneous injection, provided as autoinjectors containing 0.3 mL volume

  • tirzepatideDrug

    tirzepatide (GLP-1/GIP) will be provided in its commercial form for SC injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in body weight between treatment armsTime frame: Change from the baseline (Visit 2/Day 1) to Visit 10 (Day 57)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University Clinical Research-DeLand LLC, d/b/a Accel Research

    DeLand, Florida

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Coastal Carolina Research Center

    North Charleston, South Carolina

  • Lynn Institute of Chattanooga

    Chattanooga, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.